Acorda Therapeutics, Inc. today announced results from two ongoing, long-term safety studies of CVT-301 in people with Parkinson s that showed no differences in pulmonary function between the group receiving CVT-301 and an observational control group. These results are consistent with previously reported data from Phase 2 b and Phase 3 clinical
Dr. Verma joins the United Neuroscience team from Biogen, where he helped spark neurodegeneration therapeutic efforts by building disease area strategy, clinical development teams, experimental medicine capabilities, novel imaging technologies and a neurology drug development fellowship program in conjunction with Massachusetts General Hospital.
New Haven-based Alexion Pharmaceuticals Inc. on Monday appointed a bioscience industry veteran, who was most recently president and CEO of blood-disorder drugmaker Baxalta, as its new chief executive officer. Ludwig N. Hantson will take over Alexion`s top job immediately, following the sudden departure in December of its former CEO, David Hallal, w
ARMO BioSciences, Inc., a clinical-stage immuno-oncology company, announced that the first patient has been dosed in the Company's international Phase 3 pivotal clinical trial to evaluate its lead investigational immuno-oncology drug AM0010 in combination with FOLFOX as second-line treatment for patients with advanced pancreatic cancer.
The global market for over the counter drugs and dietary supplements reached $164.7 billion in 2016 and should reach $220.8 billion in 2021, with a compound annual growth rate of 6.0%. The study goal of this report is to understand the OTC drugs and dietary supplement market and provide five-year forecasts for the same. The objective of the study i
The Chinese infectious disease drug market is big, fast-growing and dominated by brands from outside China. This market is very important for pharmaceutical companies in North America, Europe and other developed regions that look for strong growth and high profits in the following decade. The goal of this study is to help readers achieve a comprehe
Center Point Clinical Services, creator of the world's first Siteless CRO platform, announced today study results presented in two separate posters at the Academy of Managed Care Pharmacy,# AMCP2017, Managed Care and Specialty Pharmacy annual meeting in Denver, Colorado. Joe Martinez, CEO of Center Point Clinical Services and the lead author of bot
DaVita Clinical Research, a specialty contract research organization with services spanning the full spectrum of drug and device development, has been recognized by Life Science Leader in multiple award categories of its 2017 CRO Leadership Awards. "DCR is devoted to its customers and committed to becoming the service provider of choice," said A
TOKYO, Mar 29, 2017 Eisai Co., Ltd. announced today that enrollment has commenced in Japan for MISSION AD1, a global Phase III clinical study of the in-house developed oral beta secretase cleaving enzyme inhibitor elenbecestat in patients with early Alzheimer's disease. The Phase III clinical trial program for elenbecestat consists of two global
Genentech, a member of the Roche Group, announced today that the U.S. Food and Drug Administration approved OCREVUS? as the first and only medicine for both relapsing and primary progressive forms of multiple sclerosis. The FDA s approval of OCREVUS is the beginning of a new era for the MS community and represents a significant scientific a
By a News Reporter-Staff News Editor at Biotech Week WASHINGTON A profusion of biotechnology products is expected over the next five to 10 years, and the number and diversity of new products has the potential to overwhelm the U.S. regulatory system, says a new report from the National Academies of Sciences, Engineering, and Medicine. The U.S. E
LONDON- AstraZeneca plc's New Drug Application for LYNPARZA tablets for use in platinum-sensitive, relapsed ovarian cancer patients in the maintenance setting has been accepted for priority review by the FDA- with a decision expected in the third quarter 2017.. Shares of Catalyst Biosciences Inc. soared more than 190% on Tuesday, following the go-a
JERUSALEM- The following are some of the biotech stocks that made their way onto the Day's Gainers& Losers' list of March 28, 2017. Accordingly, Catalyst's collaborator, ISU Abxis, plans to initiate a phase 1/ 2 proof-of-concept study in individuals with severe hemophilia B in the second quarter of 2017.. After phase 1/ 2 study, ISU Abxis has an op
The Global Interventional Radiology Imaging Market is expected to reach USD 23.50 billion by 2021 from USD 16.99 billion in 2016, at a CAGR of 6.7%. The global interventional radiology imaging market is expected to reach USD 23.50 billion by 2021 from USD 16.99 billion in 2016, at a CAGR of 6.7%. The key players in the market include GE Healthcare,
About JHL Biotech JHL Biotech Inc. is a biopharmaceutical startup founded by a group of industry veterans with deep experience in pharmaceutical development and operations. JHL Biotech's mission is to provide the world with low-cost medicines of exceptional quality. JHL Biotech has two world-class facilities built in accordance with United States,.
New Drug Delivery Systems Findings Has Been Reported by Researchers at University of Maryland. According to news reporting out of College Park, Maryland, by NewsRx editors, research stated, "We report the ability of hydrophobically modified polypeptoids, which are amphiphilic pseudopeptidic macromolecules, to connect across lipid bilayers and thus
According to news reporting from Fisciano, Italy, by NewsRx journalists, research stated, "Coated pellets are widely used as oral drug delivery systems, being highly accepted by patients and with several advantages with respect to single unit devices. For more information on this research see: Mathematical modeling of the drug release from an ensem
Research and Markets has announced the addition of the "Patch Pump Drug Delivery Systems Devices Therapeutics Markets Forecasts" report to their offering. This report analyzes important therapeutic segments and examines key regulatory, economic and competitive factors that represent potential barriers to commercial success. Patch Pump Drug Delivery
By a News Reporter-Staff News Editor at Biotech Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a patent application by the inventor KANIOS, DAVID, filed on April 6, 2016, was made available online on March 16, 2017. The assignee for this patent application is Noven Pharmaceuticals, Inc.. Reporters obtai
Patent Application Titled "Inductively Rechargeable External Energy Source, Charger, System and Method for a Transcutaneous Inductive Charger for an Implantable Medical Device" Published Online. By a News Reporter-Staff News Editor at Biotech Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a patent appli
The deal which is expected to close before the end of June will include two facilities in Bedford and one in Manchester, New Hampshire at which LSNE provides a range of fill/finish and lyophilisation services to drug and biopharmaceutical developers. UK- based Permira said it plans to increase capacity and extend LSNEs capabilities in manufacturing
By a News Reporter-Staff News Editor at Biotech Week- Portal Instruments, a clinical stage medical device start-up company based in Cambridge, MA received the SXSW Interactive Innovation Award in the Health, Med& Biotech category at the 20th annual South by Southwest Interactive Innovations Awards ceremony. The award was in recognition of Portal.
Sterile drug manufacturing is a growth area, and a London- based investment fund has bitten off a piece of it with the acquisition of a U.S. CDMO that specializes in the field. In 2015, Pfizer snapped up sterile injectable and biosimilar specialist Hospira for $15 billion. That came after Fresenius agreed to buy a nearly new 115,000- square-foot pl
The FDA has approved the new eczema drug dupilumab from Regeneron and Sanofi, officially launching a new drug that is likely on course to creating a megablockbuster franchise for these two partners. People with moderate-to severe atopic dermatitis cope with intense, sometimes unbearable symptoms that can impact them for most of their lives, said Ju
PARIS- Regeneron Pharmaceuticals, Inc. and Sanofi announced that the U.S. Food and Drug Administration approved DUPIXENT or dupilumab Injection, the first and only biologic medicine approved for the treatment of adults with moderate-to-severe atopic dermatitis or AD whose disease is not adequately controlled with topical prescription therapies, or.